Who is moving to which position
Resolved 12 May 2026Incoming appointee
5 itemsDeparting officer
4 items“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Onoda Michiro (大野田 道郎) is scheduled to become an adviser following his retirement as a director. The other retiring officers will not remain on the Board of Directors or the Audit & Supervisory Board.
Okanoya (岡野谷 知広): He is well versed in corporate law as an attorney and has held key positions, including professor at the Graduate School of Law at Keio University. The Company determined that he can contribute to the development of the Group, primarily through proposals and advice from a legal perspective, drawing on his advanced expertise and extensive experience. Abe (阿部 裕): He is expected to perform a management oversight function from a broad perspective, drawing on his many years of experience across various industries and his broad knowledge.
| Item | Details |
|---|---|
| Resolution date | 12 May 2026 |
| Scheduled Appointment Date | 19 June 2026. The appointments are scheduled to be formally approved at the Annual General Meeting of Shareholders scheduled for 19 June 2026 and the subsequent meeting of the Board of Directors. |
| Date of departure | 19 June 2026 |
| Name of appointee | Tamura Noriaki (田村 徳昭), Okanoya Chihiro (岡野谷 知広), Hamada Katsuhiro (濱田 佳津宏), Hiroshi Abe (阿部 裕), Nakamura Kenichi (中村 健一) |
| Appointee's new position | Director (continuing positions: Executive Officer and CCO, Head of the Pharmaceutical Sales Division, and responsible for the IT Solutions Department and Diagnostic Business Department), Outside Directors, Statutory Auditors, Outside Corporate Auditor, Executive Officer and CMO, responsible for the Reliability Assurance Division and SCM Department |
| Appointee's previous position | Executive Officer and CCO, Head of the Pharmaceutical Sales Division, and responsible for the IT Solutions Department and Diagnostic Business Department, Not disclosed, Not disclosed, Adviser, JUKI Corporation (currently serving), Executive Officer and Representative Director and President of キョーリン製薬グループ工場株式会社 |
| Appointee's date of birth | Not disclosed, Born 28 October 1957, Not disclosed, Born 22 August 1961, Not disclosed |
| Name of departing officer | Onoda Michiro (大野田 道郎), Shikauchi Noriyuki (鹿内 徳行), Matsumoto Tomoharu (松本 臣春), Ikemura Yukio (池村 幸雄) |
| Former position of departing officer | Director, Executive Officer and CMO, responsible for the Reliability Assurance Division and SCM Department, Outside Directors, Full-time Audit & Supervisory Board Member, Outside Corporate Auditor |
| New position of departing officer | Adviser, Retirement, Retirement, Retirement |
| Whether the incumbent will remain in office | Onoda Michiro (大野田 道郎) is scheduled to become an adviser following his retirement as a director. The other retiring officers will not remain on the Board of Directors or the Audit & Supervisory Board. |
| Reasons for appointment | Okanoya (岡野谷 知広): He is well versed in corporate law as an attorney and has held key positions, including professor at the Graduate School of Law at Keio University. The Company determined that he can contribute to the development of the Group, primarily through proposals and advice from a legal perspective, drawing on his advanced expertise and extensive experience. Abe (阿部 裕): He is expected to perform a management oversight function from a broad perspective, drawing on his many years of experience across various industries and his broad knowledge. |
| Subject to Approval by the General Meeting of Shareholders | Required. The appointments are scheduled to be submitted as agenda items to the Annual General Meeting of Shareholders of KYORIN Pharmaceutical Co.,Ltd. scheduled for 19 June 2026 (agenda item name: not disclosed). |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company determined that Okanoya Chihiro (岡野谷 知広) can contribute to the development of the Group through proposals and advice from a legal perspective, drawing on his advanced expertise and extensive experience in corporate law as an attorney. Abe Yutaka (阿部 裕) is expected to perform a management oversight function from a broad perspective, drawing on his many years of experience across various industries and his broad knowledge. No reasons have been provided for the other changes.